Cargando…

Alpha-synuclein oligomers: a new hope

Alpha-synuclein is a protein implicated in Parkinson’s disease and thought to be one of the main pathological drivers in the disease, although it remains unclear how this protein elicits its neurotoxic effects. Recent findings indicate that the assembly of toxic oligomeric species of alpha-synuclein...

Descripción completa

Detalles Bibliográficos
Autores principales: Bengoa-Vergniory, Nora, Roberts, Rosalind F., Wade-Martins, Richard, Alegre-Abarrategui, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663814/
https://www.ncbi.nlm.nih.gov/pubmed/28803412
http://dx.doi.org/10.1007/s00401-017-1755-1
_version_ 1783274886989348864
author Bengoa-Vergniory, Nora
Roberts, Rosalind F.
Wade-Martins, Richard
Alegre-Abarrategui, Javier
author_facet Bengoa-Vergniory, Nora
Roberts, Rosalind F.
Wade-Martins, Richard
Alegre-Abarrategui, Javier
author_sort Bengoa-Vergniory, Nora
collection PubMed
description Alpha-synuclein is a protein implicated in Parkinson’s disease and thought to be one of the main pathological drivers in the disease, although it remains unclear how this protein elicits its neurotoxic effects. Recent findings indicate that the assembly of toxic oligomeric species of alpha-synuclein may be one of the key processes for the pathology and spread of the disease. The absence of a sensitive in situ detection method has hindered the study of these oligomeric species and the role they play in the human brain until recently. In this review, we assess the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discuss the advances in our understanding of the role of alpha-synuclein in Parkinson’s disease that may be brought about by the specific and sensitive detection of distinct oligomeric species in post-mortem patient brain. Finally, we discuss current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.
format Online
Article
Text
id pubmed-5663814
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56638142017-11-16 Alpha-synuclein oligomers: a new hope Bengoa-Vergniory, Nora Roberts, Rosalind F. Wade-Martins, Richard Alegre-Abarrategui, Javier Acta Neuropathol Review Alpha-synuclein is a protein implicated in Parkinson’s disease and thought to be one of the main pathological drivers in the disease, although it remains unclear how this protein elicits its neurotoxic effects. Recent findings indicate that the assembly of toxic oligomeric species of alpha-synuclein may be one of the key processes for the pathology and spread of the disease. The absence of a sensitive in situ detection method has hindered the study of these oligomeric species and the role they play in the human brain until recently. In this review, we assess the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discuss the advances in our understanding of the role of alpha-synuclein in Parkinson’s disease that may be brought about by the specific and sensitive detection of distinct oligomeric species in post-mortem patient brain. Finally, we discuss current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications. Springer Berlin Heidelberg 2017-08-12 2017 /pmc/articles/PMC5663814/ /pubmed/28803412 http://dx.doi.org/10.1007/s00401-017-1755-1 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Bengoa-Vergniory, Nora
Roberts, Rosalind F.
Wade-Martins, Richard
Alegre-Abarrategui, Javier
Alpha-synuclein oligomers: a new hope
title Alpha-synuclein oligomers: a new hope
title_full Alpha-synuclein oligomers: a new hope
title_fullStr Alpha-synuclein oligomers: a new hope
title_full_unstemmed Alpha-synuclein oligomers: a new hope
title_short Alpha-synuclein oligomers: a new hope
title_sort alpha-synuclein oligomers: a new hope
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663814/
https://www.ncbi.nlm.nih.gov/pubmed/28803412
http://dx.doi.org/10.1007/s00401-017-1755-1
work_keys_str_mv AT bengoavergniorynora alphasynucleinoligomersanewhope
AT robertsrosalindf alphasynucleinoligomersanewhope
AT wademartinsrichard alphasynucleinoligomersanewhope
AT alegreabarrateguijavier alphasynucleinoligomersanewhope